BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26018128)

  • 21. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas.
    Bélissant O; Champion L; Thevenet H; Weinmann P; Alberini JL
    Nucl Med Commun; 2018 Jul; 39(7):652-658. PubMed ID: 29683931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer.
    Eubank WB; Mankoff DA; Takasugi J; Vesselle H; Eary JF; Shanley TJ; Gralow JR; Charlop A; Ellis GK; Lindsley KL; Austin-Seymour MM; Funkhouser CP; Livingston RB
    J Clin Oncol; 2001 Aug; 19(15):3516-23. PubMed ID: 11481358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
    Alongi P; Caobelli F; Gentile R; Stefano A; Russo G; Albano D; Baldari S; Gilardi MC; Midiri M
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):224-233. PubMed ID: 27565154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of 18F-FDG PET/CT in restaging and follow-up of patients with GIST.
    Albano D; Mattia B; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2020 Mar; 45(3):644-651. PubMed ID: 31646354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
    Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
    Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
    Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
    Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-FDG PET/CT for staging of penile cancer.
    Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S
    J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.
    Koolen BB; van der Leij F; Vogel WV; Rutgers EJ; Vrancken Peeters MJ; Elkhuizen PH; Valdés Olmos RA
    Acta Oncol; 2014 Jan; 53(1):50-7. PubMed ID: 23672678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis.
    Soubra A; Hayward D; Dahm P; Goldfarb R; Froehlich J; Jha G; Konety BR
    World J Urol; 2016 Sep; 34(9):1229-37. PubMed ID: 26847182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging.
    Caresia Aroztegui AP; García Vicente AM; Alvarez Ruiz S; Delgado Bolton RC; Orcajo Rincon J; Garcia Garzon JR; de Arcocha Torres M; Garcia-Velloso MJ;
    Tumour Biol; 2017 Oct; 39(10):1010428317728285. PubMed ID: 29025377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
    Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
    Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
    Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
    Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
    Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
    Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.